2.72

0.03% 0.0009

After Hours: 2.80 0.08 +2.94%

Synaptogenix Inc (SNPX)

Overview News Price History Financials Discussions Forecast Stock Split

Synaptogenix Inc stock is traded at $2.72, with a volume of 60,946. It is up +0.03% in the last 24 hours and down -11.72% over the past month. Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Previous Close:

$2.7191

Open:

$2.72

24h Volume:

60,946

Relative Volume:

2.14

Market Cap:

$3.69M

Revenue:

Net Income/Loss:

$-560.20K

P/E Ratio:

-1.8759

EPS:

-1.45

Net Cash Flow:

$-6.90M

1W Performance:

+2.60%

1M Performance:

-11.72%

6M Performance:

-39.69%

1Y Performance:

-56.94%

1-Day Range:

$2.49

$2.805

1-Week Range:

$2.3491

$2.8201

52-Week Range:

$2.32

$8.775

Synaptogenix Inc Stock (SNPX) Company Profile

Name

Synaptogenix Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(973) 242-0005

Address

1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK

Employee

Twitter

Next Earnings Date

Latest SEC Filings

SNPX's Discussions on Twitter

Compare SNPX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNPX Synaptogenix Inc	2.72	3.69M	0	-560.20K	-6.90M	-1.45
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Synaptogenix Inc Stock (SNPX) Latest News

Nov 13, 2024

Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com

Nov 13, 2024

Nov 05, 2024

SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN

Nov 05, 2024

Oct 15, 2024

Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR) - Defense World

Oct 15, 2024

Oct 05, 2024

Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com

Oct 05, 2024

Oct 04, 2024

Synaptogenix appoints new auditor as Morison Cogen exits By Investing.com - Investing.com UK

Oct 04, 2024

Sep 24, 2024

Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com

Sep 24, 2024

Sep 14, 2024

Synaptogenix announces new preferred stock series - Investing.com

Sep 14, 2024

Sep 11, 2024

Synaptogenix Announces $5.0 Million Financing - citybiz

Sep 11, 2024

Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com India

Sep 11, 2024

Synaptogenix secures $5 million in preferred stock financing - Investing.com India

Sep 11, 2024

Synaptogenix (NASDAQ:SNPX) Trading 2.6% Higher - Defense World

Sep 11, 2024

Sep 10, 2024

Synaptogenix extends preferred shares maturity date - Investing.com

Sep 10, 2024

Sep 02, 2024